Anditixafortide
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1]. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
Product Specifications
CAS Number
1821136-83-7
UNSPSC
12352209
Target
CXCR; Radionuclide-Drug Conjugates (RDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anditixafortide.html
Purity
99.27
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C([C@@H](NC([C@H](N(C([C@H](NC(CNC1=O)=O)CC2=CC(I)=C(C=C2)O)=O)C)CCCNC(C3=CC=C(C=C3)CNC(CN4CCN(CCN(CCN(CC4)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)N[C@H]1CC5=CC6=C(C=CC=C6)C=C5
Molecular Formula
C60H79IN14O14
Molecular Weight
1347.26
References & Citations
[1]Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6.|[2]Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Badge
Hot
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
RDC Peptide
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
